Literature DB >> 29174397

[Case-non case studies: Principles, methods, bias and interpretation].

Jean-Luc Faillie1.   

Abstract

Case-non case studies belongs to the methods assessing drug safety by analyzing the disproportionality of notifications of adverse drug reactions in pharmacovigilance databases. Used for the first time in the 1980s, the last few decades have seen a significant increase in the use of this design. The principle of the case-non case study is to compare drug exposure in cases of a studied adverse reaction with that of cases of other reported adverse reactions and called "non cases". Results are presented in the form of a reporting odds ratio (ROR), the interpretation of which makes it possible to identify drug safety signals. This article describes the principle of the case-non case study, the method of calculating the ROR and its confidence interval, the different modalities of analysis and how to interpret its results with regard to the advantages and limitations of this design.
Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Keywords:  Analyse de disproportionnalité; Biais; Bias; Case–non case study; Disproportionality analysis; Pharmaco-épidémiologie; Pharmacoepidemiology; Pharmacovigilance; Reporting odds ratio; Étude cas–non cas

Mesh:

Year:  2017        PMID: 29174397     DOI: 10.1016/j.therap.2017.08.006

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  11 in total

1.  Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study.

Authors:  Spyridon Siafis; Georgios Papazisis
Journal:  Br J Clin Pharmacol       Date:  2018-07-28       Impact factor: 4.335

2.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase®.

Authors:  Thi Thu Ha Nguyen; Anne Roussin; Vanessa Rousseau; Jean-Louis Montastruc; François Montastruc
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

3.  Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®.

Authors:  François Montastruc; Justine Benevent; Leila Chebane; Vanessa Rousseau; Geneviève Durrieu; Agnès Sommet; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2018-08-10       Impact factor: 2.953

4.  Tamoxifen administration and the risk of Parkinsonism.

Authors:  François Montastruc; Farzin Khosrow-Khavar; Agnès Sommet; Christel Renoux; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2018-09-10       Impact factor: 2.953

5.  Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality Analysis.

Authors:  Khac-Dung Nguyen; Hoang-Anh Nguyen; Dinh-Hoa Vu; Thi Thuy-Linh Le; Hoang-Anh Nguyen; Bich-Viet Dang; Trung-Nguyen Nguyen; Dang-Hoa Nguyen; Thanh-Binh Nguyen; Jean-Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

6.  Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?

Authors:  Francesco Ferrara; Carolina Mancaniello; Livia Nava; Alessandra Salierno; Raffaele Casillo; Ugo Trama; Eduardo Nava; Antonio Vitiello
Journal:  Hosp Pharm       Date:  2022-01-07

7.  Tamoxifen and the risk of Parkinsonism: a case/non-case study.

Authors:  François Montastruc; Farzin Khosrow-Khavar; Sibylle de Germay; Christel Renoux; Vanessa Rousseau; Geneviève Durrieu; Marion Montastruc; Olivier Rascol; Agnès Sommet; Maryse Lapeyre-Mestre; Justine Benevent; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2018-06-03       Impact factor: 2.953

8.  Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.

Authors:  Amayelle Rey; Benjamin Batteux; Solène M Laville; Justine Marienne; Kamel Masmoudi; Valérie Gras-Champel; Sophie Liabeuf
Journal:  Arthritis Res Ther       Date:  2019-11-08       Impact factor: 5.156

9.  Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.

Authors:  Charles Dolladille; Basile Chrétien; Laure Peyro-Saint-Paul; Joachim Alexandre; Olivier Dejardin; Sophie Fedrizzi; Gilles Defer
Journal:  Neurotherapeutics       Date:  2021-07-06       Impact factor: 6.088

10.  Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.

Authors:  Alexis Revet; François Montastruc; Anne Roussin; Jean-Philippe Raynaud; Maryse Lapeyre-Mestre; Thi Thu Ha Nguyen
Journal:  BMC Psychiatry       Date:  2020-06-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.